As overall prevalence of atrial fibrillation (AF) continues to rise, the number of patients who undergo ablation, or electrical/chemical cardioversion, to restore normal sinus rhythm continues to increase as well. As direct oral anticoagulants (DOACs) have continued to be incorporated into clinical practice for long-term anticoagulation for AF, experience with how best to manage use of DOACs during electrophysiologic procedures is evolving. This review is intended to provide health care providers with a summary of current evidence regarding the use of DOACs during cardioversion and catheter ablation and provide key considerations for their use during such electrophysiologic procedures. PubMed and MEDLINE were searched from inception through June 2018 for studies in humans comparing DOACs alone or against vitamin K antagonists (VKAs) in adult patients (> 18 yrs) who underwent cardioversion or AF catheter ablation using the following key words: "rivaroxaban," "dabigatran," "apixaban," "edoxaban," "non-vitamin K antagonists," "direct or new oral anticoagulants," "warfarin," "vitamin K antagonists," "cardioversion," "ablation of atrial fibrillation," "uninterrupted," and "catheter ablation." Four retrospective studies and three prospective trials comparing DOACs with VKA in patients undergoing cardioversion and three prospective studies in patients undergoing catheter ablation for AF were identified. Observational data and meta-analyses were also critically reviewed. Prospective trials to date suggest similar efficacy and safety with using DOACs in the setting of cardioversion and AF ablation compared to traditional therapy with VKA, with or without bridging. Injectable anticoagulant overlap can be avoided in patients receiving DOACs in the setting of cardioversion for AF. Minimal interruption in anticoagulation may be only necessary for AF ablation in those with highest bleeding risk, such as in renal dysfunction and where drug-drug interactions may increase risk for anticoagulant accumulation. Periprocedural advantages of DOACs include convenience, rapid and predictable onset of effect, improved patient satisfaction, and potential for reduced costs.
As overall prevalence of atrial fibrillation (AF) continues to rise, the number of patients who undergo ablation, or electrical/chemical cardioversion, to restore normal sinus rhythm continues to increase as well. As direct oral anticoagulants (DOACs) have continued to be incorporated into clinical practice for long-term anticoagulation for AF, experience with how best to manage use of DOACs during electrophysiologic procedures is evolving. This review is intended to provide health care providers with a summary of current evidence regarding the use of DOACs during cardioversion and catheter ablation and provide key considerations for their use during such electrophysiologic procedures. PubMed and MEDLINE were searched from inception through June 2018 for studies in humans comparing DOACs alone or against vitamin K antagonists (VKAs) in adult patients (> 18 yrs) who underwent cardioversion or AF catheter ablation using the following key words: "rivaroxaban," "dabigatran," "apixaban," "edoxaban," "non-vitamin K antagonists," "direct or new oral anticoagulants," "warfarin," "vitamin K antagonists," "cardioversion," "ablation of atrial fibrillation," "uninterrupted," and "catheter ablation." Four retrospective studies and three prospective trials comparing DOACs with VKA in patients undergoing cardioversion and three prospective studies in patients undergoing catheter ablation for AF were identified. Observational data and meta-analyses were also critically reviewed. Prospective trials to date suggest similar efficacy and safety with using DOACs in the setting of cardioversion and AF ablation compared to traditional therapy with VKA, with or without bridging. Injectable anticoagulant overlap can be avoided in patients receiving DOACs in the setting of cardioversion for AF. Minimal interruption in anticoagulation may be only necessary for AF ablation in those with highest bleeding risk, such as in renal dysfunction and where drug-drug interactions may increase risk for anticoagulant accumulation. Periprocedural advantages of DOACs include convenience, rapid and predictable onset of effect, improved patient satisfaction, and potential for reduced costs. Currently in the United States, approximately 5 million individuals have a diagnosis of atrial fibrillation (AF), and the number of patients with AF is expected to double during the next 25 years. 1 It is anticipated that similar trends will occur for European populations as well. 2 Atrial fibrillation is a significant contributor to morbidity and mortality with a 5-fold risk of stroke, a 3-fold risk of heart failure, and a doubling of mortality compared with patients without AF.
1 Cardioversion (either electrical or chemical), as well as catheter ablation, are utilized frequently to restore normal sinus rhythm in symptomatic patients. Both options carry the risk of periprocedural thromboembolism that mandates appropriate management with anticoagulation separate and distinct from long-term stroke prevention.
The introduction of the direct oral anticoagulants (DOACs) has expanded available treatment options for the prevention of thromboembolic stroke in the setting of nonvalvular AF. Phase 3 clinical trials have demonstrated that DOACs provide similar efficacy and safety, and in several instances superiority, to vitamin K antagonists (VKAs) for stroke prevention. 1, 2 Subsequently, many patients with nonvalvular AF are managed with a DOAC instead of a VKA. Similar to other pharmacotherapy advances, there is often a lack of information on how best to manage new drug therapies in unique situations. For patients with nonvalvular AF, how best to manage DOACs in the setting of electrophysiological procedures is one such example. Management strategies surrounding the use of VKA therapy are well established. However, as the use of DOACs in AF has increased, available scientific evidence to guide the management of anticoagulation with DOACs during electrophysiological procedures has significantly expanded. 3 This review will focus on available scientific literature focusing on the management of patients receiving DOAC therapy for stroke prevention in nonvalvular AF who are undergoing either cardioversion or ablation. The MEDLINE database from inception through June 2018 was searched for human studies that compared DOACs alone or against VKAs in adult patients (> 18 yrs) who underwent cardioversion or AF catheter ablation using the following keywords: "rivaroxaban," "dabigatran," "apixaban," "edoxaban," "non-vitamin K antagonists," "direct or new oral anticoagulants," "warfarin," "vitamin K antagonists," "cardioversion," "ablation of atrial fibrillation," "uninterrupted," and "catheter ablation." Management of patients receiving VKA therapy undergoing cardioversion or ablation or of patients on any oral anticoagulant undergoing electrophysiologic device implantation is beyond the scope of this review, and readers are directed to alternate sources for information. 4 Four retrospective studies and three prospective trials comparing DOACs with VKA in patients undergoing cardioversion and three prospective studies in patients undergoing catheter ablation for AF were identified. Observational data and meta-analyses were also critically reviewed. Current DOAC studies focusing on cardioversion and ablation will be discussed in this review with regard to the potential risks and benefits associated with anticoagulation management strategies in advance and during these procedures. Key questions addressed in this review include timing of DOAC administration, whether the interruption of anticoagulation is necessary for patients receiving a DOAC, and safety and efficacy outcomes associated with periprocedural use of DOACs.
Prevention of Thromboembolism Secondary to Electrical or Chemical Cardioversion
Cardioversion by electrical or pharmacological means is an effective method for terminating AF and restoring normal sinus rhythm, usually in patients with symptoms. Patients with hemodynamic instability and those with a known AF onset of < 48 hours can undergo cardioversion immediately.
1 If the duration of AF has been 48 hours or longer, or the duration is unknown, the periprocedural risk of thromboembolism can be as high as 5-7% without anticoagulant therapy. [5] [6] [7] Current guidelines recommend providing therapeutic anticoagulation for at least 3 weeks before and at least 4 weeks after cardioversion to minimize thromboembolic risk.
1, 2 Although never evaluated in randomized controlled trials, observational data suggest that the use of anticoagulation in this fashion lowers the risk of thromboembolism to approximately 0.5-1.6%. 6, 8 Prior to the availability of DOACs, VKA with or without unfractionated heparin (UFH) or low molecular weight heparin (LMWH) was the sole option for managing thromboembolic risk in the pericardioversion period. Observational data have also demonstrated that thromboembolism is significantly more common at an international normalized ratio (INR) of 1.5-2.4 before cardioversion than an INR of 2.5 or higher (0.93% vs 0%, respectively; p=0.012), suggesting the importance of maintaining a therapeutic INR in the pericardioversion period. 9 Data generated in observational studies suggest that thromboembolic risk is highest in the first 72 hours after cardioversion, and the majority of events occur within 10 days of the procedure. 10 The pathophysiology of these thrombotic events after cardioversion is thought to be secondary to migration of thrombi dislodged at the time of cardioversion, as well as the formation and subsequent migration of new thrombi that form while atrial function is still depressed in the post cardioversion period. This second mechanism is supported by data from transesophageal echocardiography (TEE) trials that demonstrate atrial mechanical dysfunction may be present for several weeks post cardioversion despite restoration of sinus rhythm on the electrocardiogram (ECG). 11 An alternative guideline recommended approach is the use of TEE to rule out the presence of a thrombus in the left atrium or left atrial appendage. 1, 12 Patients with AF (≥ 48 hrs) will initiate anticoagulation with either a DOAC or VKA, then immediately undergo a TEE. If no thrombus is detected, the cardioversion can proceed without 3 weeks of precardioversion anticoagulation. However, these patients do receive at least 4 weeks of post cardioversion anticoagulation. Continuing anticoagulation beyond 4 weeks should be based on the patient's risk of stroke (CHA 2 DS 2 -VASc score), and not on the basis of successful cardioversion. A TEE-guided approach is supported by the results of the ACUTE trial (Assessment of Cardioversion Using Transesophageal Echocardiography). 13 In this trial 1222 patients demonstrated comparable risk for thromboembolic events with both the conventional strategy of 3 weeks of warfarin before cardioversion, and with the TEE-guided strategy of short-term anticoagulation with intravenous UFH or warfarin and immediate cardioversion (0.5% and 0.8%, respectively; p=0.50). 13 The TEE-guided group in the ACUTE trial had significantly lower risk of bleeding in the pericardioversion period compared with the conventional group (2.9% vs 5.5%, respectively; p=0.03), most likely related to the longer duration of anticoagulation in the conventional group.
Management of Patients Receiving DOACs Undergoing Cardioversion
Compared to VKA therapy, the use of DOACs offers theoretical advantages in the setting of cardioversion including pharmacokinetic differences (Table 1) , allowing for faster therapeutic anticoagulation, reduced time to cardioversion, avoidance of parenteral anticoagulant bridging to therapeutic INR periprocedurally, and improved patient satisfaction. Despite these potential advantages, initial concerns surrounded whether there would be similar efficacy and safety of DOACs compared with VKA in this setting. Evolving evidence has demonstrated these concerns to be unfounded. Although not all DOACs have been prospectively studied in the setting of cardioversion, comparable safety and efficacy have been demonstrated from retrospective analyses and three randomized trials. Each of the phase 3 pivotal trials establishing the role of DOACs in AF included patients who underwent cardioversion, and subanalyses of these patients provide insights on utilizing DOACs in this setting. [15] [16] [17] [18] The RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy) established the direct thrombin inhibitor, dabigatran, as a reasonable option for stroke prevention in AF. 15 During the trial, 1270 patients underwent 1983 cardioversions (83.5% electrical). No significant differences were reported in the rates of stroke or systemic embolism at 30 days between patients receiving dabigatran 110 mg (0.8%), dabigatran 150 mg (0.3%), or warfarin (0.6%). In the ROCKET AF trial (Rivaroxaban Once Daily Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), which established a role for rivaroxaban 20 mg/day for stroke prevention in AF, 285 patients underwent 375 cardioversions (50% electrical). The risk of stroke or systemic embolism in the pericardioversion period was the same between patient receiving rivaroxaban (1.9%) and warfarin (1.9%) after 2.1 years of follow-up. 16 During the ARISTOLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) evaluating apixaban 5 mg twice/day compared to warfarin for stroke prevention in AF, no stroke events were observed at 30 days post cardioversion (no information on type provided) in either the apixaban or warfarin arm during 743 total cardioversions. 17 A similar observation was seen for edoxaban 60 mg/day in the ENGAGE AF-TIMI 48 trial (Effective Anticoagulation with Factor Xa Next Generation in Atrial FibrillationThrombolysis in Myocardial Infarction). No stroke events were observed in either the edoxaban or warfarin arm at 30 days during 632 total electrical cardioversions in 365 patients. 18 The totality of evidence from post-hoc analyses supports the safety and efficacy of DOACs for patients undergoing cardioversion who have been receiving a DOAC for long-term stroke prevention.
Event rates reported in post-hoc analyses of phase 3 trials ranged from none in the ARISTO-TLE trial to 1.9% in the ROCKET AF trial. Differences in event rates between the trials is likely explained by the lower-risk patients in the ARISTOTLE trial, with a mean CHADS 2 score of 1.8 compared with the higher-risk patients in ROCKET AF, who had a median CHADS 2 score of 3. 16, 17 The follow-up time for monitoring events in the ROCKET AF trial was also much longer than the other three trials (2.1 yrs vs 30 days). Since the majority of patients enrolled in these studies were classified as having persistent or permanent AF (68-84%), the percent undergoing cardioversion was low (range of 1.7-7%). [19] [20] [21] Additional evidence, especially from randomized controlled trials evaluating the initiation of a DOAC specifically for patients undergoing cardioversion, was needed.
Additional observational evidence supporting the use of DOACs in cardioversion was recently published. 22 In Overall thromboembolic (three events, 0.3%) and bleeding events (six events, 0.5%) in the pericardioversion period was low. Similar favorable results were observed in XANTUS, a prospective observational study assessing the safety and effectiveness of rivaroxaban in 6784 patients in real world practice. 23 Overall 502 patients underwent cardioversion during the follow-up time frame. Three patients (0.6%) experienced a transient ischemic attack (TIA) within 30 days of the procedure. In each case patients underwent electrical cardioversion.
Data evaluating DOAC use in the cardioversion setting are also becoming available from prospective, randomized trials. Assuming a 30-day event rate after cardioversion of 1% with warfarin, an appropriately powered noninferiority analysis would need approximately 20,000-40,000 patients. Because this size trial is probably not logistically or financially feasible for this indication, trial size has been based on the number of patients undergoing cardioversion from the RE-LY trial, 15 suggesting that this would provide clinically meaningful information of efficacy and safety of DOACs compared to traditional therapy with a VKA.
The X-VeRT trial (eXplore the efficacy and safety of once-daily oral riVaroxaban for the prevention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion) was the first prospective study evaluating the use of a DOAC for prevention of thromboembolism in the cardioversion setting. 24 Investigators enrolled 1504 patients with In these instances, rivaroxaban or a VKA (AEinjectable anticoagulant) was to be provided 1-5 days prior to and for 6 weeks post cardioversion. For delayed cardioversions, patients received anticoagulation with rivaroxaban or a VKA for 3-8 weeks as needed to achieve adequate anticoagulation. Therapies were continued for 6 weeks after cardioversion. The primary efficacy outcome of the trial was the composite of stroke, systemic embolism, myocardial infarction (MI), or cardiovascular death in the modified intention-to-treat (mITT) analysis. 24 The primary safety analysis was major bleeding as defined by the International Society of Thrombosis and Haemostasis (ISTH). 25 Successful cardioversion occurred in 86.8% of 1167 patients who underwent cardioversion (97.6% electrical). The median time from randomization to cardioversion was similar (1 day) in patients randomized to rivaroxaban or VKA if early cardioversion was performed, whereas it was significantly shorter for patients on rivaroxaban compared to VKA in the delayed cardioversion group (22 days [21] [22] [23] [24] [25] [26] vs 30 days [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] , respectively; p<0.001). At 6 weeks after cardioversion, overall rates of the primary end point were similar between groups (0.51% vs 1.02%, rivaroxaban vs VKA respectively; relative risk [RR] = 0.50; 95% confidence interval [CI] 0.15-1.73). 24 No significant differences were reported between the two treatment arms in the primary outcome for patients undergoing either early or delayed cardioversion. In addition, no significant differences in the rates of bleeding (major, critical site, intracranial, or fatal) were observed between the rivaroxaban and VKA arms. 24 The second prospective trial evaluated edoxaban in an open-label fashion in patients with AF undergoing electrical cardioversion (ENSURE-AF trial, EdoxabaN vs warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation). 26 Investigators enrolled 2199 patients with nonvalvular AF undergoing planned electrical cardioversion who were randomized 1:1 to edoxaban 60 mg/day or warfarin (with enoxaparin bridge). Patients could undergo early cardioversion, guided by TEE, or a delayed cardioversion. Edoxaban had to be given at least 2 hours before cardioversion in the TEE-guided stratum and at least 21 days in the non-TEE-guided stratum. All patients received 28 days of anticoagulation after cardioversion. The primary efficacy end point was the composite of stroke, systemic embolism, MI, or cardiovascular death 4 weeks after cardioversion in the ITT population. The primary safety end point was the combination of major and clinically elevant nonmajor bleeding as defined by the ISTH criteria. 25 A majority (89%) of patients were able to achieve normal sinus rhythm. 26 The medium time from randomization to cardioversion was 2 days in both groups in the TEE-guided stratum (54%) and 23 days in both groups in the non-TEE-guided stratum (46%). The incidence of the primary efficacy end point 4 weeks after cardioversion was not significantly different between edoxaban compared to warfarin (0.46% vs 1.0%; odds ratio [OR] = 0.46; 95% CI 0.12-1.43), respectively. There were no significant differences in event rates in the TEE-guided stratum (0.34% vs 0.84%) or the non-TEE-guided stratum (0.59% vs 1.12%; edoxaban vs warfarin, respectively). The primary safety end point occurred in 1% of both groups at 4 weeks after cardioversion, with no significant differences in the rates of major, or any, bleeding events. There were no intracranial hemorrhages, one life-threatening bleed in each group, and one fatal bleed in the warfarin group.
Last, the EMANATE trial (Eliquis evaluated in acute cardioversion coMpared to usuAl treatmeNts for AnticoagulaTion in subjEcts with atrial fibrillation) prospectively evaluated apixaban compared to heparin transitioned to a VKA in patients undergoing cardioversion. 27 Investigators enrolled 1500 patients with echocardiographically confirmed AF and < 48 hours of prior anticoagulation, and randomized them to apixaban or heparin plus VKA titrated to a goal INR of 2.0-3.0. Apixaban could have been given as 5 mg twice/day for a minimum of 5 doses (n=247), or with an initial 10-mg loading dose at least 2 hours (n=331) before cardioversion. Dosage reduction was allowed in those meeting two of the following criteria: age ≥ 80 years, weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/ dl. Anticoagulation was continued for 30 (AE7) days after cardioversion. Overall, 1038 active (89% electrical) and 300 spontaneous cardioversions occurred during the trial. Compared to heparin/VKA, the rate of stroke was significantly reduced with the use of apixaban (0% apixaban vs 0.8% heparin/VKA; p=0.015). Rates of major bleeding were also similar between groups, with three patients in the apixaban group and six patients in the heparin/VKA group experiencing a major bleed (p=0.338). Overall, these results are in alignment with the prospective trials for rivaroxaban and edoxaban (Table 2) .
Three recent meta-analyses including approximately 3500 patients from the RE-LY, ROCKET AF, ARISTOTLE, and X-VeRT trials [28] [29] [30] found similar RR or OR values for stroke and systemic embolism compared to traditional therapy with VKA. Another meta-analysis of 4000 patients that included ENGAGE AF-TIMI 48 31 reported similar findings to the earlier analysis for stroke and systemic embolism (RR 0.84; 95% CI, 0.34-2.04) and major bleeding (RR 1.12; 95% CI, 0.52-2.42) compared with VKA therapy. Several prospective, randomized trials are under way to further expand our knowledge in this area, but based on current safety and efficacy findings it would seem that use of DOACs periprocedurally around cardioversion is appropriate. If a DOAC is determined to be the best option for anticoagulation in patient undergoing cardioversion, careful attention to adherence needs to be a priority because reliable DOAC-specific clotting assays are not widely available to ensure that appropriate anticoagulation has been established. 32 
Time to Cardioversion
An obvious advantage of using DOACs in patients undergoing cardioversion includes reduced time to cardioversion due to faster therapeutic anticoagulation. Provided no clot is present on TEE, a DOAC can be initiated within a few hours prior to cardioversion without need for therapeutic overlap of LMWH or UFH as would be required with VKA initiation. If a TEE-guided strategy is unavailable, a minimum delay of 3 weeks for precardioversion anticoagulation is required as previously described. The X-VeRT trial reported even shorter times to delayed cardioversion with DOACs, which may be due to the fact that patients on warfarin do not always keep their INR between 2.0 and 3.0 for the 3 weeks prior to cardioversion. 24 These findings are supported by a small study (n=106) that evaluated time to cardioversion for patients receiving dabigatran or warfarin. 33 Mean time to cardioversion for patients on dabigatran was significantly shorter than for patients receiving warfarin (54 days vs 82 days; respectively, p=0.001). A Danish registry including 1230 patients receiving dabigatran or warfarin also evaluated mean times to cardioversion. 34 Patients receiving dabigatran had a mean time to cardioversion of 4 weeks compared to 6.9 weeks for warfarin. Also at 4 weeks, 50% of dabigatran-treated patients had undergone cardioversion compared to 27% of warfarin-treated patients (p<0.005). The generally shorter times to cardioversion with DOACs can lead to fewer delays in care, potentially reducing costs. 35 Patient satisfaction may also be greater with DOAC agents in cardioversion compared with traditional approaches, even if the cardioversion is delayed. In the X-VeRT trial, patients undergoing delayed cardioversion on rivaroxaban reported greater convenience (80.3% vs 66.7%), better effectiveness (38.8% vs 34.4%), and higher global satisfaction (81.7% vs 67.5%; all p values <0.0001) compared to patients receiving VKA, respectively. No significant difference was noted in side effect rates between treatment groups. Similar results were reported by patients undergoing the early approach. 35 
Prevention of Thromboembolism Secondary to Catheter Ablation
Cather ablation has emerged as a viable option for the control of heart arrhythmias, especially in symptomatic patients, where high success rates have been reported. 36 However, catheter ablation increases the risk of thromboembolic events, even in low-risk patients. Several mechanisms may be at play for the increased risk of thrombosis, including thrombus formation on the catheter or within the sheath following transeptal puncture to access the left atrium, endothelial damage, and "stunning" of the atrial myocardium. 37 Appropriate anticoagulation is needed prior to, during, and after the procedure to mitigate the thromboembolic risks associated with ablation. Current North American and European guidelines recommend 3 weeks of systemic anticoagulation at a therapeutic level prior to catheter ablation in patients with AF for longer than 48 hours, or for unknown duration of AF. Alternatively, TEE may be used to exclude the presence of left atrial thrombus allowing for the procedure to be performed within a shorter timeframe.
1, 2 Transesophageal echocardiography may also be useful in confirming the absence of left atrial clot in patients taking DOAC therapy as adherence cannot be readily verified.
The classic approach to the management of anticoagulation prior to the availability of the DOACs involved a typical periprocedural strategy for warfarin therapy. Warfarin would be discontinued 3-5 days prior to the ablation, and the patients would be bridged with heparin or enoxaparin, which would be held the morning of the procedure and then resumed postprocedure when the patient is clinically stable. During the procedure itself, once the left atrium has been accessed, it is common practice to use UFH, given as a bolus, to achieve an activated clotting time (ACT) between 300 and 400 seconds for the duration of the procedure. Periodic checking of the ACT with the administration of supplemental UFH boluses as needed is done in order to maintain target ACT. Postprocedure anticoagulation with UFH is brought back to more typical levels utilizing activated partial thromboplastin time (aPTT) monitoring to facilitate bridging back to a therapeutic INR with warfarin. In general, guidelines recommend that therapeutic anticoagulation be maintained for at least 8 weeks post procedure. If the patient remains in normal sinus rhythm 2-3 months after procedure, stopping long-term anticoagulation can be considered. Importantly, failure to achieve and maintain a therapeutic INR in the previous 3 weeks or failure to achieve and maintain an ACT of > 300 seconds during the procedure have been associated with an elevated risk of thrombosis in the periprocedural window. 38 It is against this historical backdrop that alternative management strategies for anticoagulation for ablation procedures can be considered in the present day.
Although appropriate anticoagulation during AF catheter ablation is necessary to minimize thromboembolic risk, it also increases the risk of bleeding. Bleeding complications associated with the procedure include hemopericardium, cardiac tamponade, and bleeding complications at the vascular access site. 39 Given these concerns, a strategy of uninterrupted warfarin therapy in the preprocedural period has emerged. Available evidence has demonstrated that bleeding complications were actually lower with uninterrupted warfarin compared with a bridging strategy, while also reducing both clinical and silent thromboembolic events. 40 As such, current guidelines recommend that patients on warfarin continue therapy (INR = 2.0-3.0) through the ablation procedure. 2 Similar to concerns regarding the use of DOACs in patients undergoing cardioversion, as DOACs emerged as treatment options for patient with AF it was unclear if these agents would provide similar efficacy and safety to uninterrupted VKA therapy in the setting of catheter ablation. Several publications have evaluated the safety and efficacy of DOACs versus VKAs in the setting of AF catheter ablation. Overall these studies describe positive outcomes that support DOAC use in this clinical setting. 41, 42 There are, of course, two competing interests to consider. One is managing potential complications, such as cardiac perforation, and the other is avoiding systemic embolization. As more evidence for the use of DOACs in the setting of AF ablation becomes available, varying treatment approaches have been investigated. Recent investigations highlight a more streamlined approach of either minimally interrupted DOAC therapy (holding one or two DOAC doses prior to, then resuming therapy post procedure) or potentially uninterrupted DOAC therapy throughout the ablation procedure. In either of these approaches, DOAC therapy is typically recommended to resume 4-6 hours after procedure provided hemostasis has been established. To date, published evidence for DOACs in the setting of AF ablation comes from observational data sets, most utilizing a minimally interrupted approach, indicating no adverse safety signal associated with DOAC therapy in the periprocedural period, as reviewed here later.
Management of Patients Receiving Oral Direct Thrombin Inhibitors Undergoing AF Ablation
To date, many of the published reports on the use of dabigatran in the setting of ablation are nonrandomized studies that describe experience with dabigatran alone or compare outcomes between dabigatran versus uninterrupted warfarin. Different dabigatran dosing protocols have been employed, including interrupted versus uninterrupted approaches, and some studies have explored whether ACT values were achieved and maintained with supplemental UFH. These were important factors to consider when attempting to determine the best approach to managing a patient on dabigatran undergoing catheter ablation.
In a multicenter, observational, and prospective study, 145 patients on periprocedural dabigatran, dosed at 150 mg twice/day were compared with 145 matched patients taking uninterrupted warfarin therapy. 40 Patients in the dabigatran group held the morning dose and resumed therapy 3 hours after the radiofrequency ablation procedure. During the procedure both groups received a standard 10,000 unit bolus of UFH, with further weight-adjusted doses of heparin to maintain an ACT between 300 and 400 seconds. The dabigatran group showed a higher incidence of bleeding complications, including late-onset pericardial tamponade and the composite outcome of bleeding and thromboembolism, compared to patients in the warfarin group. In univariate analysis, dabigatran use and age older than 75 years were independent predictors of bleeding and combined bleeding and thromboembolism. In contrast, researchers reported that 212 patients receiving uninterrupted dabigatran, dosed at 150 mg twice/ day, had similar bleeding and thromboembolic outcomes compared to 251 patients on uninterrupted warfarin therapy undergoing AF ablation. Of note, initial UFH dosing in this study was given as a weight-based dose of 200 units/kg, with a target ACT of > 400 seconds in all but 22 patients in the study. 39 Prospectively collected data from a registry describes 376 patients on dabigatran (150 mg twice/day), withheld for 1-2 days preprocedure, and 623 patients on uninterrupted VKA. 43 The study found no evidence of increased thromboembolic or hemorrhagic risk with either strategy. Similar results were observed in a casecontrol study where equivalent safety and efficacy was reported for dabigatran (150 mg twice/day, withheld 24 hrs preprocedure, resumed 4 hrs postprocedure) and uninterrupted warfarin. 44 All patients received UFH to a goal ACT of 300-350 seconds prior to the catheter ablation of AF. Furthermore, a multicenter retrospective analysis of 882 patients demonstrated that patients on uninterrupted dabigatran had similar risk for major bleeding as patients on interrupted/bridged warfarin or uninterrupted warfarin therapy, although those in the uninterrupted warfarin group had an increase in major complications, 12/276 (4.3%), compared with 3/374 (0.8%) in dabigatran and 6/232 (2.6%) in the bridged group (p=0.01). 45 Another small study reported that the risk of bleeding and thromboembolic complications was no different in 173 patients receiving uninterrupted dabigatran (150 mg twice/day) than in 190 patients receiving uninterrupted warfarin therapy during the periprocedural period of AF ablation. 41 Of note, the aPTT was an independent predictor of periprocedural complications in the dabigatran group.
Additional information comes from one small randomized controlled trial comparing dabigatran, dosed at 150 mg twice/day (45 patients), compared with VKA (45 patients), both using an interrupted strategy, with therapy stopped 1 day prior to the procedure and resuming after the procedure once hemostasis was achieved. Both groups received UFH at a dose of 100 units/kg with an ACT goal intraprocedurally of 300-400 seconds. Overall the results were comparable between the two groups, with a higher risk of minor bleeding in the VKA group (OR 3.2; 95% CI 1. 28-8.49; p=0.015) . 46 The dose of dabigatran used in this trial was 110 mg twice/day. Two recent meta-analyses analyzing published evidence comparing outcomes with dabigatran versus warfarin in the setting of catheter ablation of AF reported no differences in bleeding or thromboembolic events between the two groups. 47, 48 Both analyses highlighted the nonrandomized observational nature of the studies and variability in the drug administration protocols. Regardless, both analyses suggested similar safety and efficacy between dabigatran and warfarin in patients undergoing catheter ablation for AF.
Recently results from the RE-CIRCUIT (Randomized Evaluation of dabigatran etexilate Compared to warfarin in pulmonaRy vein ablation; assessment of different periproCedUral anticoagulation sTrategies) trial became available. RE-CIRCUIT was a randomized, open-label multicenter controlled trial comparing dabigatran versus warfarin for prevention of thromboembolic events in 635 patients undergoing catheter ablation. 49 Patients had to be older than 18 years of age, with documented AF within the prior 24 months, and eligible for dabigatran therapy according to local usage criteria. Dabigatran was dosed at 150 mg twice/day, and warfarin was titrated to an INR of 2.0-3.0. Anticoagulation was given for 4-8 weeks prior to the procedure, continued uninterrupted during the ablation, and then continued for 8 weeks after procedure. Unfractionated heparin was administered to achieve an ACT of > 300 seconds during the procedure. The primary end point, major bleeding according to ISTH criteria, was lower in the dabigatran arm (1.6%) as compared to the warfarin arm (6.9%, p<0.001). Dabigatran was also associated with a numerical decrease in periprocedural tamponade and groin hematomas. One thromboembolic event occurred during the entire trial in the warfarin treatment group. 49 Overall, the results of this well-designed randomized trial support the previous observational evidence that patients on dabigatran can safely be continued on therapy in an uninterrupted fashion when catheter ablation is performed.
Management of Patients Receiving Oral Factor Xa Inhibitors Undergoing AF Ablation
Similar to dabigatran, observational or retrospective studies evaluating the use of oral factor Xa inhibitors have suggested similar safety outcomes when compared to uninterrupted warfarin therapy during AF catheter ablation.
In a single-center observational study, 272 patients receiving either 15 mg or 20 mg/day of rivaroxaban therapy in an uninterrupted fashion and were matched by age, gender, and type of rhythm disorder with an equal number of patients who received uninterrupted warfarin therapy during catheter ablation procedures. Both groups received UFH at a dose of 50 units/ kg if the baseline ACT was > 170 seconds or 60 units/kg if the baseline ACT was < 170 seconds, with supplemental UFH doses to maintain the ACT between 270 and 300 seconds during the procedure. No differences were noted for major bleeding or thromboembolism between groups, but there was a slight but significant increased incidence of nontamponade pericardial bleeding in the warfarin group. 50 A large multicenter observational study comparing 321 patients receiving uninterrupted rivaroxaban to 321 patients receiving uninterrupted warfarin prior to undergoing ablation was reported. 51 Patients on rivaroxaban were either on 15 mg once/day or 20 mg once/day for AF. Both groups received a 10,000-unit bolus of UFH prior to the procedure along with supplemental UFH doses in order to maintain a goal ACT of 300-400 seconds. No differences were noted between the groups regarding major bleeding, thromboembolic complications, or minor bleeding complications. However, the HAS-BLED score was higher in the VKA cohort compared to the rivaroxaban arm of the study.
In the previously described XANTUS study, 173 patients on chronic rivaroxaban therapy underwent catheter ablation during the follow-up period. 23 At 30 days, two patients (1.2%) experienced a stroke, and five patients (2.9%) experienced a major bleed. In addition, two meta-analyses, each incorporating eight studies, showed equivalent periprocedural efficacy, risk of bleeding, and risk of thromboembolism when comparing VKA with rivaroxaban regimens. 52, 53 However, significant variation in the dosing and administration protocols in the individual studies limited the interpretability of the meta-analyses.
Apixaban has likewise demonstrated a comparable safety profile to VKA when used in an uninterrupted protocol in the peri-ablation period. However, heterogeneity in the UFH protocol and ACT profiles were again observed between the study groups.
One hundred five patients receiving uninterrupted apixaban therapy were compared to 237 patients receiving uninterrupted warfarin in a small observational evaluation of patients undergoing catheter ablation. 54 Both groups received UFH to maintain a goal ACT of 300-350 seconds during the procedure. No differences were noted between the groups with respect to major or minor bleeding or thromboembolic complications. Of note, patients on apixaban therapy required a higher dose of UFH to achieve a target ACT.
Similar results were observed in two additional retrospective cohort studies, both of which evaluated uninterrupted apixaban therapy compared to uninterrupted VKA therapy in patients undergoing catheter ablation. 55, 56 Although the number of publications evaluating uninterrupted apixaban (in patients received their morning dose on the day of procedures) in the setting of catheter ablation is smaller compared to studies evaluating dabigatran and rivaroxaban, the results with apixaban therapy appear promising despite the aforementioned limitations of the published trials.
Adding to the promising observational data for the effectiveness of factor Xa inhibitors in the setting of catheter ablation, several randomized controlled trials have been published in recent years (Table 3) . Findings from a prospective randomized trial of uninterrupted rivaroxaban compared with uninterrupted warfarin in patients undergoing catheter ablation for AF have been summarized by the Venture-AF (ActiVe-controlled multi-cENTer stUdy with blind-adjudication designed to evaluate the safety of uninterrupted Rivaroxaban and uninterrupted vitamin K antagonists in subjects undergoing cathEter ablation for nonvalvular Atrial Fibrillation) investigators. 57 In all, 124 patients received rivaroxaban 20 mg once/day while 124 patients were titrated to an INR of 2.0-3.0 with warfarin therapy. Unfractionated heparin was used intraprocedurally to achieve a goal ACT of 300-400 seconds. The total dose of heparin needed was lower in the rivaroxaban arm. The incidence of major bleeding and thromboembolic events was low and not statistically different between groups. The single major bleeding event and two thromboembolic events (one stroke, one vascular death) accrued during the study period occurred in the warfarin arm.
Uninterrupted therapy with apixaban versus warfarin (target INR 2.0-3.0) in patients undergoing catheter ablation was evaluated in a prospective randomized open-label trial. 58 Two hundred patients with drug-resistant AF were managed on apixaban (5 mg or 2.5 mg twice/ day based on approved dosing criteria) or warfarin for 4 weeks prior to ablation. Unfractionated heparin was administered to both groups to achieve an ACT of > 300 seconds, although the duration of oral anticoagulation postprocedure was not reported. The primary outcome was the occurrence of ischemic stroke, TIA, silent cerebral infarction, or major bleeding at 7 days post procedure. Overall, three primary outcome events occurred in each group (p=1.00) providing further evidence that uninterrupted apixaban is a reasonable option for prevention of thromboembolic events in patients undergoing catheter ablation. Despite generally favorable results to date with either uninterrupted or minimally interrupted approaches to the management of DOAC therapy for ablation, there remain several important areas of uncertainty that need to be addressed adequately in order to confirm the preferred approach for each patient population. These include (i) the verification of the safety and efficacy of periprocedural DOAC therapy, in particular the effect on major and minor bleeding, as well as silent\em-bolization cerebral ischemia; (ii) the clarification of the impact of DOAC therapy on intraprocedural anticoagulation, as well as the impact on the ACT; (iii) the appropriate time to resume DOAC therapy postprocedure; (iv) the management of periprocedural bleeding complications (this may be facilitated by the availability of specific reversal agents); and (v) the use of uninterrupted or minimally interrupted DOAC therapy during ablation. Many of these questions are currently being addressed by ongoing randomized and controlled clinical trials assessing the safety and efficacy of periprocedural DOAC therapy as an adjunct to ablation procedures.
Key Considerations for DOAC Therapy in Electrophysiologic Procedures
Evidence suggests that uninterrupted anticoagulation at the time of procedure is a favored approach and is not associated with increases in bleeding during cardioversion or ablation in patients at low risk for bleeding (Figure 1) . However, whether to interrupt OAC requires full consideration of type of anticoagulant used, the patient's underlying bleed risk, and bleed risk of the procedure. The Electrophysiology Section Leadership Council of the American College of Cardiology classifies cardioversion and ablation of AF as low risk for bleeding generally with possible intermediate bleeding risk under extreme circumstances. 4 There is early evidence in the literature for using uninterrupted therapy for cardiac procedures such as cardioversion, AF ablation, and cardiac device implantation with minimal bleeding outcomes. Yet, interruptions in therapy still may be considered for patients at highest risk for bleeding based on individual patient factors, including renal and hepatic function, potential interactions with other drugs, and lack of availability for reversal of anticoagulation. Policies regarding interruption of anticoagulation and management of bleeding if it occurs should be developed and available in the electrophysiology lab. Key questions for the development of interrupted protocols are the length of time that anticoagulant therapy should be interrupted and how long the interruption should continue (i.e., when should the interruption begin and for how long should it last?). Patients should be asked specifically about the indication for their anticoagulant prior to the procedure and a careful assessment of appropriate dosing, presence of drug interactions, and evaluation of renal and hepatic function should be performed in order to minimize risk preoperatively (Table 4) . If anticoagulant interruption is deemed necessary, both European and U.S. guidelines suggest performing procedures with minimal to no bleeding risk at trough concentration of DOACs (either 12 or 24 hrs after the last dose, depending upon the dosing interval), and resuming therapy as soon as 6 hours after the procedure. 3, 4 With this approach, only one dose of dabigatran or apixaban (dosed twice/day) would be missed (Figure 1 ). Avoiding peak concentration at the time of procedure is important. In interventions associated with risk for minor or major bleeding events, respectively, discontinuing the DOAC 24-48 hours preoperatively in patients with normal renal function is recommended; a longer duration may be necessary if renal function is impaired. For procedures where complete hemostasis occurs, resumption of the DOAC agent 6-8 hours after the intervention is appropriate. 3 In higher risk procedures, anticoagulation may be interrupted and resumption may be delayed for up to 48 hours, with the realization that risk for cardioembolism increases with sustained periods of interruption. Unfortunately, to date there is no safety or efficacy data supporting the use of a reduced dose of DOACs in patients with AF after a surgical procedure.
Conclusion
Emerging data suggest that DOACs have similar safety and efficacy outcomes as VKA when given during cardiovascular procedures, such as cardioversion and catheter ablation of AF. Advantages for the use of DOACs in these procedures include convenience, rapid and predictable onset of action, avoidance of bridging with parenteral anticoagulation especially when therapeutic interruption of OAC is deemed necessary, and patient satisfaction. Consensus guidelines suggest that most cardiac procedures carry low risk for bleeding and can be performed with an uninterrupted approach; however, therapeutic interruption may still be prudent for patients with highest risk for bleeding, including those with impaired renal function. 
